Cartesian Therapeutics Inc
RNAC6.490USD
+0.210+3.34%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
168.76MMarket Cap
LossP/E TTM
More Details of Cartesian Therapeutics Inc Company
Cartesian Therapeutics, Inc. is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. It leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. The Company’s lead asset, Descartes-08, is a chimeric antigen receptor T-cell therapy (CAR-T) entering Phase 3 clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-B-cell maturation antigen (BCMA) CAR-T being evaluated in a Phase 1 trial in patients with multiple myeloma. Descartes-08 is an autologous chimeric antigen receptor T-cell therapy product targeting B-cell maturation antigen in clinical development for generalized myasthenia gravis and systemic lupus erythematosus.
Cartesian Therapeutics Inc Info
Ticker SymbolRNAC
Company nameCartesian Therapeutics Inc
IPO dateJun 22, 2016
CEOBrunn (Carsten)
Number of employees66
Security typeOrdinary Share
Fiscal year-endJun 22
Address7495 New Horizon Way
CityFREDERICK
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code21703
Phone13013488698
Websitehttps://www.cartesiantherapeutics.com/
Ticker SymbolRNAC
IPO dateJun 22, 2016
CEOBrunn (Carsten)
Company Executives of Cartesian Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Murat Kalayoglu, M.D., Ph.D.
Dr. Murat Kalayoglu, M.D., Ph.D.
Independent Director
Independent Director
505.02K
+2600.00%
Dr. Carsten Brunn, Ph.D.
Dr. Carsten Brunn, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
149.68K
+119434.00%
Dr. Emily English, Ph.D.
Dr. Emily English, Ph.D.
Chief Operations Officer
Chief Operations Officer
75.95K
+24000.00%
Dr. Milos Miljkovic, M.D.
Dr. Milos Miljkovic, M.D.
Chief Medical Officer
Chief Medical Officer
40.55K
+23427.00%
Mr. Blaine Davis
Mr. Blaine Davis
Chief Financial Officer
Chief Financial Officer
38.62K
+26409.00%
Mr. Patrick J. (Pat) Zenner
Mr. Patrick J. (Pat) Zenner
Lead Independent Director
Lead Independent Director
6.42K
+2600.00%
Dr. Kemal Malik
Dr. Kemal Malik
Independent Director
Independent Director
2.60K
+2600.00%
Mr. Timothy C. (Tim) Barabe
Mr. Timothy C. (Tim) Barabe
Independent Director
Independent Director
--
--
Dr. Timothy A. (Tim) Springer, Ph.D.
Dr. Timothy A. (Tim) Springer, Ph.D.
Director
Director
--
--
Dr. Nishan M. de Silva, M.D.
Dr. Nishan M. de Silva, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Murat Kalayoglu, M.D., Ph.D.
Dr. Murat Kalayoglu, M.D., Ph.D.
Independent Director
Independent Director
505.02K
+2600.00%
Dr. Carsten Brunn, Ph.D.
Dr. Carsten Brunn, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
149.68K
+119434.00%
Dr. Emily English, Ph.D.
Dr. Emily English, Ph.D.
Chief Operations Officer
Chief Operations Officer
75.95K
+24000.00%
Dr. Milos Miljkovic, M.D.
Dr. Milos Miljkovic, M.D.
Chief Medical Officer
Chief Medical Officer
40.55K
+23427.00%
Mr. Blaine Davis
Mr. Blaine Davis
Chief Financial Officer
Chief Financial Officer
38.62K
+26409.00%
Mr. Patrick J. (Pat) Zenner
Mr. Patrick J. (Pat) Zenner
Lead Independent Director
Lead Independent Director
6.42K
+2600.00%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, Feb 7
Updated: Sat, Feb 7
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Springer Timothy A
33.23%
Seven One Eight Three Four Irrevocable Trust
17.52%
Fidelity Management & Research Company LLC
8.29%
Singer (Michael S.)
2.65%
TAS Partners, L.L.C.
2.52%
Other
35.79%
Shareholders
Shareholders
Proportion
Springer Timothy A
33.23%
Seven One Eight Three Four Irrevocable Trust
17.52%
Fidelity Management & Research Company LLC
8.29%
Singer (Michael S.)
2.65%
TAS Partners, L.L.C.
2.52%
Other
35.79%
Shareholder Types
Shareholders
Proportion
Individual Investor
40.78%
Corporation
20.04%
Investment Advisor
18.56%
Investment Advisor/Hedge Fund
4.27%
Hedge Fund
1.67%
Research Firm
0.15%
Venture Capital
0.10%
Bank and Trust
0.06%
Pension Fund
0.02%
Other
14.35%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
184
6.46M
24.86%
-1.16M
2025Q3
181
6.69M
25.71%
-763.38K
2025Q2
206
22.27M
85.81%
-1.28M
2025Q1
226
22.94M
90.08%
+138.68K
2024Q4
230
22.26M
88.90%
-105.22K
2024Q3
229
20.22M
92.77%
+6.58M
2024Q2
235
14.41M
85.20%
+9.02M
2024Q1
233
3.74M
346.71%
-1.42M
2023Q4
240
3.82M
71.00%
-922.87K
2023Q3
251
3.63M
70.60%
-1.17M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Springer Timothy A
8.64M
33.22%
+22.36K
+0.26%
Apr 14, 2025
Seven One Eight Three Four Irrevocable Trust
4.56M
17.52%
--
--
Apr 14, 2025
Fidelity Management & Research Company LLC
2.16M
8.29%
-178.34K
-7.64%
Sep 30, 2025
Singer (Michael S.)
687.06K
2.64%
-20.00K
-2.83%
Nov 18, 2025
TAS Partners, L.L.C.
656.51K
2.52%
+126.72K
+23.92%
Apr 14, 2025
BlackRock Institutional Trust Company, N.A.
577.37K
2.22%
-4.66K
-0.80%
Sep 30, 2025
Invus Public Equities Advisors, LLC
563.27K
2.17%
--
--
Sep 30, 2025
The Vanguard Group, Inc.
520.72K
2%
+24.36K
+4.91%
Sep 30, 2025
Kalayoglu (Murat)
502.42K
1.94%
-8.88K
-1.74%
Apr 14, 2025
MPM BioImpact LLC
380.00K
1.46%
-306.01K
-44.61%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Virtus LifeSci Biotech Clinical Trials ETF
0.54%
Invesco Nasdaq Biotechnology ETF
0.02%
ProShares Ultra Nasdaq Biotechnology
0.02%
iShares Micro-Cap ETF
0.02%
iShares Biotechnology ETF
0.01%
ALPS Medical Breakthroughs ETF
0%
Global X Russell 2000 ETF
0%
Invesco Russell 2000 Dynamic Multifactor ETF
0%
iShares Russell 2000 Value ETF
0%
Proshares Ultra Russell 2000
0%
View more
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.54%
Invesco Nasdaq Biotechnology ETF
Proportion0.02%
ProShares Ultra Nasdaq Biotechnology
Proportion0.02%
iShares Micro-Cap ETF
Proportion0.02%
iShares Biotechnology ETF
Proportion0.01%
ALPS Medical Breakthroughs ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
Invesco Russell 2000 Dynamic Multifactor ETF
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
Mar 28, 2024
Merger
30→1
Mar 28, 2024
Merger
30→1
Mar 28, 2024
Merger
30→1
Mar 28, 2024
Merger
30→1
Date
Ex-dividend Date
Type
Ratio
Mar 28, 2024
Merger
30→1
Mar 28, 2024
Merger
30→1
Mar 28, 2024
Merger
30→1
Mar 28, 2024
Merger
30→1
